Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Bluegreen who wrote (7475)	10/12/1998 11:16:00 AM
From: aknahow	Read Replies (1) \| Respond to of 17367

Partial up date of U.K. graphs as of Oct 9. The Lab report graph now has data for week 38 of 98 compared to 1997. Total lab reports for the week were 43 of which 22 were type B and 21 were type C. This is way up over 1997 when there were 18 total cases, 11 type B and 7 type C. phls.co.uk Note the graph provides cumulative data. I have started saving the information to determine what has happened for the week. Remember the 38th week was about 4 weeks ago. I do not really see a use for this information. It might help one estimate total accrual rate and it might help one think about the U.K. attitude toward the need for a drug.

To: Bluegreen who wrote (7475)	10/12/1998 4:14:00 PM
From: aknahow	Read Replies (1) \| Respond to of 17367

Psoriasis article. See last paragraph. pslgroup.com "Perhaps the most exciting of the new drugs to combat psoriasis are the fusion proteins, usually a combination of unique molecules with antibody fragments, he said. "These are proteins that block the activation of T-cells that lead to the development of psoriasis. Although not yet approved by the FDA, they have performed well in clinical trials. Just a few injections can result in dramatic improvement and may be the long-term answer to controlling the disease," Dr. Lebwohl said." Wonder who is involved in these clinical trials?